1
|
Kriegsmann K, Longuespée R, Hundemer M, Zgorzelski C, Casadonte R, Schwamborn K, Weichert W, Schirmacher P, Harms A, Kazdal D, Leichsenring J, Stenzinger A, Warth A, Fresnais M, Kriegsmann J, Kriegsmann M. Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information. Proteomics Clin Appl 2018; 13:e1800035. [PMID: 30035857 DOI: 10.1002/prca.201800035] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Revised: 07/04/2018] [Indexed: 12/16/2022]
Abstract
OBJECTIVE Tissue slides analyzed by MS imaging (MSI) are stained by H&E (Haematoxylin and Eosin) to identify regions of interest. As it can be difficult to identify specific cells of interest by H&E alone, data analysis may be impaired. Immunohistochemistry (IHC) can highlight cells of interest but single or combined IHC on tissue sections analyzed by MSI have not been performed. METHODS We performed MSI on bone marrow biopsies from patients with multiple myeloma and stained different antibodies (CD38, CD138, MUM1, kappa- and lambda). A combination of CK5/6/TTF1 and Napsin-A/p40 is stained after MSI on adenocarcinoma and squamous cell carcinoma of the lung. Staining intensities of p40 after MSI and on a serial section are quantified on a tissue microarray (n = 44) by digital analysis. RESULTS Digital evaluation reveals weaker staining intensities after MSI as compared to serial sections. Staining quality and quantity after MSI enables to identify cells of interest. On the tissue microarray, one out of 44 tissue specimens shows no staining of p40 after MSI, but weak nuclear staining on a serial section. CONCLUSION We demonstrated that single and double IHC staining is feasible on tissue sections previously analyzed by MSI, with decreased staining intensities.
Collapse
Affiliation(s)
- Katharina Kriegsmann
- Department of Hematology, Oncology and Rheumatology, University of Heidelberg, 69117, Heidelberg, Germany
| | - Rémi Longuespée
- Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany
| | - Michael Hundemer
- Department of Hematology, Oncology and Rheumatology, University of Heidelberg, 69117, Heidelberg, Germany
| | | | | | | | - Wilko Weichert
- Institute of Pathology, TU Munich, 80333 Munich, Germany
| | - Peter Schirmacher
- Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany
| | - Alexander Harms
- Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany
| | - Daniel Kazdal
- Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany
| | - Jonas Leichsenring
- Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany
| | | | - Arne Warth
- Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany
| | - Margaux Fresnais
- Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, 69120 Heidelberg, Germany.,German Cancer Consortium (DKTK)-German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany
| | | | - Mark Kriegsmann
- Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany
| |
Collapse
|